Verano Holdings (VRNO) Net Income towards Common Stockholders (2021 - 2026)
Verano Holdings' (VRNO) quarterly Net Income towards Common Stockholders came in at -$17.8 million in Q1 2026, down 54.78% year-on-year from -$39.4 million in Q1 2025, and up 90.28% on a QoQ basis from -$183.4 million in Q4 2025.
Verano Holdings (VRNO) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$17.8 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 54.78% year-over-year to -$17.8 million in Q1 2026; TTM through Mar 2026 was -$264.2 million, a 24.2% increase from a year earlier, with the FY2025 full-year figure at -$257.9 million, up 24.56% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$17.8 million, up from -$183.4 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for VRNO reached as high as $45.9 million in Q1 2022 and fell as low as -$272.7 million in Q4 2024.
- Historically, Net Income towards Common Stockholders has averaged -$56.4 million across 5 years, with a median of -$19.2 million in 2025.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 66.72% in 2022 and fell as far as 3065.98% in 2022.
- Year by year, Net Income towards Common Stockholders stood at -$216.1 million in 2022, then soared by 64.24% to -$77.3 million in 2023, then sank by 252.85% to -$272.7 million in 2024, then jumped by 32.74% to -$183.4 million in 2025, then soared by 90.28% to -$17.8 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$17.8 million in Q1 2026, -$183.4 million in Q4 2025, and -$43.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Verano Holdings | 1.99 Bn | 1.91 Bn | 98.98 Mn | -17.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.82 Mn |
| Dec 31, 2025 | -183.41 Mn |
| Sep 30, 2025 | -43.83 Mn |
| Jun 30, 2025 | -19.15 Mn |
| Mar 31, 2025 | -11.52 Mn |
| Dec 31, 2024 | -272.71 Mn |
| Sep 30, 2024 | -42.57 Mn |
| Jun 30, 2024 | -21.76 Mn |
| Mar 31, 2024 | -4.82 Mn |
| Dec 31, 2023 | -77.29 Mn |
| Sep 30, 2023 | -17.76 Mn |
| Jun 30, 2023 | -13.06 Mn |
| Mar 31, 2023 | -9.24 Mn |
| Dec 31, 2022 | -216.11 Mn |
| Sep 30, 2022 | -42.99 Mn |
| Jun 30, 2022 | -9.85 Mn |
| Mar 31, 2022 | 45.87 Mn |
| Dec 31, 2021 | -6.83 Mn |
| Sep 30, 2021 | -11.96 Mn |
| Jun 30, 2021 | -29.59 Mn |